Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States.
Wilfredo R MatiasJacob M KoshyEllen H NagamiVictor KovacLetumile R MoengErica S ShenoyDavid C HooperLawrence C MadoffMiriam B BarshakJennifer A JohnsonChristopher F RowleyBoris JulgElizabeth L HohmannJacob E LazarusPublished in: Open forum infectious diseases (2022)
A large, ongoing multicountry outbreak of human monkeypox has the potential to cause considerable morbidity and mortality. Therapeutics for the treatment of smallpox, a related Orthopoxvirus , may be used and affect the natural history of monkeypox. We present 3 patients from our hospitals treated with tecovirimat, a pan- Orthopoxvirus inhibitor currently available under an expanded access investigational new drug protocol for monkeypox.
Keyphrases
- endothelial cells
- end stage renal disease
- newly diagnosed
- randomized controlled trial
- healthcare
- ejection fraction
- chronic kidney disease
- small molecule
- emergency department
- pluripotent stem cells
- peritoneal dialysis
- risk assessment
- prognostic factors
- combination therapy
- open label
- study protocol
- electronic health record